News
Screening of Fetal Aneuplodies Whereby Non-invasive Prenatal Test (NIPT)
This is the final project plan of the CA on “Screening of fetal aneuplodies whereby non-invasive prenatal test (NIPT)”. Included are the external comments on
Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on Regorafenib (Stivarga©) The purpose of the assessment is to evaluate Regorafenib (Stivarga©) indicated
MammaPrint® – Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer assessment
This is the final project plan of the Other Technologies CA on MammaPrint® – Added value of using gene-expression signature for adjuvant chemotherapy decisions in
Final assessment report on midostaurin (Rydapt©) in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy
Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on midostaurin (Rydapt©) This is the assessment of the relative effectiveness of midostaurin (Rydapt©)
EMA-EUnetHTA Parallel Consultation
Parallel consultation between EUnetHTA and the European Medicines Agency As of July 2017, EUnetHTA and the European Medicines Agency (EMA) offer parallel consultations on evidence
EMA-EUnetHTA meeting June 2017 – Final minutes
20170608 – EMA-EUnetHTA Meeting Minutes – FINAL
EMA-EUnetHTA meeting Dec 2016 – Final minutes
EMA-EUnetHTA meeting Dec 2016 – Final minutes
EMA-EUnetHTA Joint Work Plan for 2017-2020
This is the EMA-EUnetHTA Joint Work Plan for 2017-2020 EMA-EUnetHTA work plan 2017 – 2020 – for publication
An analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report
An analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report WP7 Activity 1 Report Template for deliverable 7.1 Annex 1_agency data Annex
Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)
This is the final project plan of the pharma JA on Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive
